January 14, 2026

Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation

he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.

Dana-Farber

May 05, 2023

Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma

In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control an...

The ASCO Post

March 28, 2024

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior...

The ASCO Post

February 08, 2023

Higher Rate of Clonal Hematopoiesis in Pediatric Cancer Survivors May Be Linked With Treatment-Induced STAT3 Gene Mutations and Risk of Adverse Long-Term Outcomes

A large study by researchers at St. Jude Children’s Research Hospital has identified a higher rate of clonal hematopoiesis as well as significant enrichment in treatment-related STAT3 gene mutations i...

The ASCO Post

October 01, 2023

Dana-Farber Research Publication 10.1.2023

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors.

Dana-Farber

August 13, 2024

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

Roswell Park Comprehensive Cancer Center

May 23, 2024

Clinical Trial Mounts Two-Pronged Attack Against Relapsed/Refractory Pediatric Sarcomas

In recent years investigators have launched a growing number of clinical trials evaluating the efficacy of combining chemotherapy and immunotherapy in a two-pronged attack against cancer.

Roswell Park Comprehensive Cancer Center

February 06, 2025

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-c...

The ASCO Post

September 03, 2024

Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

Dana-Farber